MSBio Posted - 1 day ago

$ABEO in less than 4 months you will see sp doubled catalyzed by re-submission. The drug really worked for the terrible disease. It will be approved in a year of so depending on FDA classify it as a class 1 or class 2 re-submission.

RDeneronow Posted - 2 days ago

$ABEO Seems like they want to Steal shares... Simply Wall St highlighting major risk on negative equity even though share offer is complete , Cash runway is good into 2026 AND major Catalysts coming. 🚀

TheLearnerEarner Posted - 2 days ago

$ABEO over 35%+ compound gains so far from this SWING TRADE 💰 FOLLOW to be in 1st 🥇 Always FREE trade idea alerts 📟

RDeneronow Posted - 2 days ago

$ABEO Wow !!!! Not a year forecast.... $21 lower price target at a Much shorter time frame... 61 days is Waaaayyyy better... Hopefully she knows something!!! 🚀

AnaChart Posted - 2 days ago

$ABEO https://anachart.com/wp-content/uploads/ana_temp/1715889719_soc-img.jpg

kenny91655 Posted - 3 days ago

$ABEO Cantor's Kluska reduced price target to 21 from 36

invest2021_now Posted - 3 days ago

$ABEO

RDeneronow Posted - 3 days ago

$ABEO https://www.webcaster4.com/Player/Index?webcastId=50614&g=3949bcf7-60f3-4b8d-8d4e-326caf839e66&uid=6476821&sid= The Q1 conference call is Very interesting. Everyone should listen , PAY close attention to the 15:30 minute mark. SCC , Squamous Cell Carcinoma often develops on large wound areas. There have No cases of SCC after ABEO's treatment. 👀 However its still too early to put it on their labeling. https://www.accessmedicinenetwork.com/posts/malignant-wounds-squamous-cell-carcinoma-scc This plus long term durability..... JMHO 🤔! ABEO's $300K per treatment will be adjusted to a much higher price...

_StockTrader Posted - 3 days ago

Real-Time Stock Data $ABEO Price: 4.72 Volume: 604432 Market Cap: 197396992 PE Ratio: -2.4842105 Powered by: AITX

PPT_for_me Posted - 4 days ago

$ABEO Sorry to all the paper hands that sold this and bought GME 🤡

PPT_for_me Posted - 4 days ago

$ABEO https://investors.abeonatherapeutics.com/events Audio here, easy double from here

Estimize Posted - 4 days ago

$ABEO beats the Estimize EPS Consensus by 2c and misses the Estimize Revenue Consensus by $0.19M. Reports FQ1 earnings of -53c EPS and ... http://www.estimize.com/abeo/fq1-2024?utm_content=beat_or_miss&utm_medium=tweet&utm_source=stocktwits

epsguid Posted - 4 days ago

$ABEO reported a loss of $0.53, consensus was ($0.47) via @eWhispers #epsmiss http://eps.sh/d/abeo

Stock_Titan Posted - 4 days ago

$ABEO Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress https://www.stocktitan.net/news/ABEO/abeona-therapeutics-reports-first-quarter-2024-financial-results-and-fs97debea5fo.html

Doggo2010 Posted - 4 days ago

$ABEO Alright. I’m in. Let’s do this

Alone Posted - 5 days ago

$ABEO when is the earning date?

DollarDan1 Posted - 5 days ago

$ABEO Buying this dip before earnings tomorrow.

MSBio Posted - 5 days ago

$ABEO IBRX lost 57% due to an CRL due to issue with their CMO. Resubmission doubled sp. FDA approval doubled sp again

jasonlin280 Posted - 5 days ago

$ABEO we are getting shit on

MSBio Posted - 5 days ago

$ABEO Company has the clear timeline to address FDA's questions and re-submission with occur in Q3. Looking for 20-40% sp increase prior to approval, and then taking off after approval. Overall BLA approval rate is greater than 90%. You will be happy in less than a year or sooner.

invest2021_now Posted - 5 days ago

$ABEO

GolfMo Posted - 6 days ago

$ABEO Well this stop is in a free fall

jasonlin280 Posted - 1 week ago

$ABEO isn’t today’s earnings date?

Jimmy1940 Posted - 1 week ago

$ABEO reversal time - on better than average volume...

ccledez Posted - 1 week ago

$ABEO this is almost the safest hold in bios. When there's a crl for manufacturing. Always goes back to pre decision price. Which was about $7.50 From here, you're talking about $3 gain per share. 4.17 average and will buy one for time

Tdorsey1776 Posted - 1 week ago

$ABEO So what to focus on? "The Phase 3 VITAL study met both co-primary endpoints. That is, treatment of RDEB patients with EB-101 resulted in statistically significant improvements in wound healing and pain reduction. Wound healing was measured from baseline all the way to 6 months of treatment. Wound healing percentage improvement from baseline of 81.4% was observed (trial endpoint was 50%) in EB-101 treated randomize wounds, compared to only a 16.3% improvement in control group. 16.3% vs 81.4%...homerun. The co-primary endpoint dealing with pain showed a statistically significant pain reduction associated with wound dressing changes compared to control over a 6-month period. The treatment with EB-101 established a mean pain reduction associated with wound dressing of 3.08 points from baseline, compared to control which only established a 0.90 mean pain reduction."

Tdorsey1776 Posted - 1 week ago

$ABEO The timeline on this is a perfect example of the FDA's shortcomings. February the FDA tells ABEO BLA looks good, no advisory meeting necessary, facilities inspection clean...insider buying....then CRL for a manufacturing issue or clarification. I'm viewing it as an opportunity to gain exposure, ride this through refile and new PDUFA. Did I leave out anything?

kenny91655 Posted - 1 week ago

$ABEO Reached out to ABEO IR for clarification on earnings date, no response.

kenny91655 Posted - 1 week ago

$ABEO 9 or 10 months till PDUFA imo. We will see this drift with the bio market. Biden signaling more tariffs to China does not bode well for inflation at home. Higher rates affect money losing biotech's.

Tdorsey1776 Posted - 1 week ago

$ABEO B 5k shares $4.15, will look to keep adding on dips. CRL all about time, refile...approval...etc